Since 1992, researchers from academic epilepsy, governmental agencies such the Food and Drug Administration, the National Institutes of Health, and pharmaceutical and device industry researchers have been meeting on a biennial basis to discuss ways to expedite new epilepsy therapies to patients. These meetings have been exchanges of ideas, discussions of roadblocks to therapeutic development, dialogues about regulatory strategies, and the sharing of successful approaches.
Discussions at the AEDD have led to:
- Implementation of new trial designs
- Important re-analyses and insights drawn from previous epilepsy trials
- Identification of new regulatory pathways, notably the approval of new antiepileptic drugs for monotherapy use
- New therapeutic understandings of clinical trial methodology and analysis to the larger neurological community and to clinicians who ultimately use these therapies
We are planning to have the next AEDD meeting in the Spring of 2021. When available, details regarding the meeting can be found at our website, www.aedtrials.com or contact Mary Ann Brodie: email@example.com